A fourth dose of DTPa-IPV vaccine given to 4-6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11-12 months of age

• Published in: Scandinavian journal of infectious diseases Vol. 37; no. 3; pp. 221 - 229
• Main Authors: Nilsson, Lennart, Faldella, Giacomo, Jacquet, Jeanne-Marie, Storsaeter, Jann, Silfverdal, Sven-Arne, Ekholm, Leif
• Format: Journal Article
• Language: English
• Published: Basingstoke Informa Healthcare 2005; Taylor & Francis
• Subjects: Antibodies, Bacterial - blood; Antibodies, Viral - blood; Bacterial diseases; Bacterial diseases of the nervous system. Bacterial myositis; Biological and medical sciences; Child; Child, Preschool; Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage; Diphtheria-Tetanus-acellular Pertussis Vaccines - adverse effects; Diphtheria-Tetanus-acellular Pertussis Vaccines - immunology; Ent and stomatologic bacterial diseases; Female; Human bacterial diseases; Human viral diseases; Humans; Immunization, Secondary; Infectious diseases; Italy; Male; Medical sciences; MEDICIN; MEDICINE; Poliovirus; Poliovirus Vaccine, Inactivated - administration & dosage; Poliovirus Vaccine, Inactivated - adverse effects; Poliovirus Vaccine, Inactivated - immunology; Sweden; Vaccines, Combined - administration & dosage; Viral diseases; Viral diseases of the nervous system; Italy; Sweden; Scandinavia; Europe; Picornaviridae; Vaccination; Enterovirus; Prevention; Dose; Child; Protection; Age; Human; Nervous system diseases; Respiratory disease; Antibody; Oral administration; Acute anterior poliomyelitis; Vaccine; Diphtheria; Whooping cough; Virus; Antigen; Infection; Immunoprophylaxis; Viral disease; Central nervous system disease; Bacteriosis; Poliovirus 3; Tetanus; Spinal cord disease; Comparative study
• ISSN: 0036-5548; 1651-1980; 1651-1980
• DOI: 10.1080/00365540410020884

Healthy 4-6 y old children from Italy and Sweden immunized with DTPa and inactivated or oral polio vaccines at 3, 5 and 11-12 months of age, received 1 dose of combined DTPa-IPV (n=211) or DTPa+IPV as separate doses (n=205) in a randomized trial. The pre-booster seroprotection rates were similar in each group and were above 60% against all antigens except diphtheria (31.3% and 37.0%) and PT (21.5% and 25.9%) in the DTPa-IPV and DTPa+IPV groups, respectively. At least 99.5% of subjects had seroprotective antibody levels against diphtheria, tetanus and polioviruses and ≥96% showed a vaccine response to each pertussis antigen after vaccination. Post-booster antibody levels increased at least 51-fold for anti-diphtheria and anti-tetanus, at least 18-fold for anti-pertussis antibodies and at least 32-fold for antibodies against all 3 poliovirus types, compared to prior levels. DTPa-IPV was comparable to DTPa+IPV in terms of seroprotection rates and mean antibody levels against each vaccine antigen. Similar reactogenicity profiles were observed between groups including swelling >50 mm [13% (9.1, 18.7) vs 17% (12.4, 23.4)] or involving an adjacent joint [0% (-,-) vs 1.5% (0.3, 4.3)] and were consistent with previous reports. The combined DTPa-IPV vaccine could be used to add DTP valences to the IPV vaccine currently given to children in Scandinavia and Italy at 4-6 y of age and reinforce protection against 4 diseases.